Pular para o conteúdo principal
Ranking Invest

SNY - Sanofi

Segmento: HealthcareSanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Análise Ranking Invest

Valuation estimado
$ 95.99 Bi
Valor de Mercado
$ 101.90 Bi
Sobrepreço (AV)+6.2%
IVR
0.94A companhia vale 0,94 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.23O valuation alternativo equivale a 23% do valor de mercado da companhia.
MLL
0.23O lucro líquido dos controladores em 16 trimestres equivale a 23% do valor de mercado.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 73.73 Bi

Dívida Líquida

$ 13.06 Bi

L4T

$ 6.30 Bi

MM4T

13.46%

Indicadores Básicos

ROE

8.54%

Índices de Previsibilidade

Receita Líquida

D0.09

Lucro

C0.45

Margem

C0.38

Índices de Tendência

Receita Líquida

D1.98

Lucro

E-1.74

Margem

E-2.93

Índices de Endividamento

DIV/PAT

0.18

DIV/L4T

2.07

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.